<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04776811</url>
  </required_header>
  <id_info>
    <org_study_id>PDGS3</org_study_id>
    <nct_id>NCT04776811</nct_id>
  </id_info>
  <brief_title>Evaluation of Accuracy of Guardian Sensor 3 in Diabetes Patients on Peritoneal Dialysis</brief_title>
  <official_title>Evaluation of Accuracy of Guardian Sensor 3 in Diabetes Patients on Peritoneal Dialysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Elaine Chow</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medtronic Diabetes</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Chinese University of Hong Kong</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Assessment of performance (precision and accuracy) of Guardian Sensor™ 3 as compared with a&#xD;
      gold standard reference laboratory method (YSI glucose) in diabetes patients on peritoneal&#xD;
      dialysis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Mean absolute relative difference (MARD)</measure>
    <time_frame>5 minutes</time_frame>
    <description>MARD of sensor versus YSI glucose</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Median absolute relative difference (MedARD)</measure>
    <time_frame>5 minutes</time_frame>
    <description>MedARD of sensor versus YSI glucose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Consensus Error grid analysis</measure>
    <time_frame>5 minutes</time_frame>
    <description>% sensor values in regions A and B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent accuracy</measure>
    <time_frame>5 minutes</time_frame>
    <description>System readings within 15%, 20%, 30%, 40% and greater than 40% of YSI values</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypoglycemia detection rates</measure>
    <time_frame>15 minutes</time_frame>
    <description>True and false hypoglycemia notification rate, correct and missed hypoglycemia detection rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hyperglycemia detection rates</measure>
    <time_frame>15 minutes</time_frame>
    <description>True and false hyperglycemia notification rate, correct and missed hyperglycemia detection rates</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>User satisfaction</measure>
    <time_frame>2 weeks</time_frame>
    <description>Diabetes Satisfaction Treatment Questionnaire score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between CGM metrics, HbA1c and fructosamine</measure>
    <time_frame>2 weeks</time_frame>
    <description>Correlation between CGM metrics, HbA1c and fructosamine</description>
  </secondary_outcome>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Diabetes Mellitus (Diagnosis)</condition>
  <condition>End Stage Renal Disease</condition>
  <condition>Dialysis</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Continuous glucose monitoring system</intervention_name>
    <description>Medtronic Guardian Connect with Guardian Sensor 3</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Diabetes patients on continuous ambulatory peritoneal dialysis&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Type 1 or 2 diabetes mellitus diagnosed for at least 3 months&#xD;
&#xD;
          2. On continuous ambulatory peritoneal dialysis (CAPD) for at least 3 months&#xD;
&#xD;
          3. Male or female age ≥ 18 years old and ≤ 75 year old.&#xD;
&#xD;
          4. Women who are not pregnant, lactating or planning a pregnancy during their&#xD;
             participation in the clinical study.&#xD;
&#xD;
          5. Willingness, ability and commitment to comply with the testing, procedure and&#xD;
             follow-up outlined in this protocol including (but not limited to) frequency of clinic&#xD;
             visits and use of pre-specified glucose monitoring devices.&#xD;
&#xD;
          6. Willingness to abstain from swimming during their participation in the measurement&#xD;
             phase.&#xD;
&#xD;
          7. In the opinion of the investigator, absence of any physical limitations, addictive&#xD;
             diseases, or underlying medical conditions (including mental health) that may preclude&#xD;
             the patient from being a good study candidate.&#xD;
&#xD;
          8. Written informed consent to participate in the study provided by the patient.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Poorly controlled diabetes mellitus with HbA1c&gt;11%&#xD;
&#xD;
          2. Peritonitis within 1 month&#xD;
&#xD;
          3. On icodextrin PD solutions&#xD;
&#xD;
          4. Planned for switching to hemodialysis or living donor transplant in future 3 months&#xD;
&#xD;
          5. Currently pregnant, as demonstrated by a positive pregnancy test at screening&#xD;
&#xD;
          6. Any active acute or chronic disease or condition that, in the opinion of the&#xD;
             investigator, might interfere with the performance of this study.&#xD;
&#xD;
          7. Any active acute or chronic infectious disease that, in the opinion of the&#xD;
             investigator, would pose an excessive risk to study staff.&#xD;
&#xD;
          8. Current use or recent exposure to any medication that in the opinion of the&#xD;
             investigator could have an influence on the patient's ability to participate in this&#xD;
             study or on the performance of the test device.&#xD;
&#xD;
          9. Extensive skin changes/diseases that preclude wearing the required number of devices&#xD;
             on normal skin at the proposed application sites (e.g., extensive psoriasis, recent&#xD;
             burns or severe sunburn, extensive eczema, extensive scarring, extensive tattoos,&#xD;
             dermatitis herpetiformis).&#xD;
&#xD;
         10. Have a known allergy to medical-grade adhesives, or known hypersensitivity to any of&#xD;
             the products used in the study.&#xD;
&#xD;
         11. Blood donation of more than 500 ml within the last three months&#xD;
&#xD;
         12. Currently participating in another investigational study protocol where the testing or&#xD;
             results may interfere with study compliance, diagnostic results, or data collection.&#xD;
&#xD;
        13 Has a MRI scan, CT scan, or diathermy scheduled during the proposed study participation.&#xD;
&#xD;
        14. An identified protected vulnerable patient (including but not limited to those in&#xD;
        detention, or a prisoner).&#xD;
&#xD;
        15. Women of reproductive potential who are unwilling to adopt contraceptive measures&#xD;
        during the study period 16. Patients with history of pacemaker and prosthesis implantation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elaine Chow, PhD, MBChB</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chinese University of Hong Kong</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Elaine Chow, MBChB</last_name>
    <phone>+85235051549</phone>
    <email>e.chow@cuhk.edu.hk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Elaine Chow</name>
      <address>
        <city>Hong Kong</city>
        <state>None Selected</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elaine Chow</last_name>
      <email>e.chow@cuhk.edu.hk</email>
    </contact>
    <investigator>
      <last_name>Jack Ng</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>February 27, 2021</study_first_submitted>
  <study_first_submitted_qc>February 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 2, 2021</study_first_posted>
  <last_update_submitted>August 2, 2021</last_update_submitted>
  <last_update_submitted_qc>August 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Chinese University of Hong Kong</investigator_affiliation>
    <investigator_full_name>Elaine Chow</investigator_full_name>
    <investigator_title>Clinical Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Failure, Chronic</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

